Clinic Invent has at its disposal a number of technologies available in clinical biomedicine. The newest technologies offered are:

Therapeutics:
Methods and compounds for preventing, treating and diagnosing an inflammatory condition
NR2B-selective NMDA-receptor antagonists for the treatment of immune-mediated inflammatory diseases
Novel inhibitors targeting colonization and virulence of gastrointestinal pathogens
Use of transglutaminase 1-liposomes for topical enzyme replacement therapy for transglutaminase 1 deficient lamellar ichthyosis
Ergosterol-biosynthesis inhibitor and influenza virus infection
Cholesterol emulsion and supplementary food for the treatment of Smith-Lemli-Opitz syndrome
GD2 target upregulation by EZH2 inhibition in cancer therapy

Diagnostics:
Quinoline-3-carboxamide compounds and their use in diagnosis
Compounds and methods for the detection of calprotectin
Novel biomarkers for recurrent tonsillitis
Complex-specific standardisation of immunological methods for the quantification of S100A12
Method for assessing by CASA the fertilizing potential of sperm based on longitudinal axis rotation
Method for establishing an individual physical activity program for a subject for re-ducing an individual risk of the subject for developing a cardiovascular disease
Sperm stratification

Devices:
A method of enriching and/or isolating a target cell population from a suspension of cells
Protective cap for standard microcirculatory videomicroscopes
Swim prosthesis
System for investigation of a small animal

Monoclonal antibodies
All antibodies are monoclonal unless stated otherwise. For further detailed information on an antibody of interest, please contact Dr. Elke Benkhart at any time.

Antigen Antibody Publication
mouse VCAM-1 6C7 (rat IgG1) Engelhardt et al. J Clin Invest., 1998, 102(12):2096-2105
mouse Endomucin V.5C7 (rat IgG1) Brachtendorf et al. Developmental Dynamics, 2001, 222:410-419; Morgan et al. Blood, 1999, 93(1):165-175
mouse Endomucin V.1A7 (rat IgG1) Brachtendorf et al. Developmental Dynamics, 2001, 222:410-419; Morgan et al. Blood, 1999, 93(1):165-175
human 3pK 3p8-1 (mouse IgG2a, kappa) not yet published
influenza NS1 NS1.23.1 (mouse) Ehrhardt et al. Journal of Virology, 2007, 81(21):12097- 12100

Animal models
For further detailed information on an animal model of interest, please contact Dr. Elke Benkhart at any time.

Mouse Model Disease Publication
CREM-lbΔC-X Atrial fibrillation Müller et al. Journal of Biological Chemistry, 2005, 280(8):6906-6914; Stümpel et al. Front Pharmacol. 2018 Jul 5;9:706
MBII-85del+/- Prader-Willi syndrome Skryabin et al. PLoS Genet., 2007, 3(12):e235:2529-2539
K14-4-1BB TG Pruritus-like skin disease Technology Offer
TTP-/- x MRP14-/- Psoriasis Technology Offer